ALKS
Alkermes plc · Healthcare
Insiders sold $10.0M of Alkermes plc in the last 12 months and bought none
ALKS over the last year
ALKS after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
213 insider filings since 2016, newest first
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
Craig C. Hopkinson · EVP R&D, Chief Medical Officer
Christian Todd Nichols · SVP and Chief Commercial Officer
Nancy Lynn Md Snyderman · Director
Craig C. Hopkinson · EVP R&D, Chief Medical Officer
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
Craig C. Hopkinson · EVP R&D, Chief Medical Officer
Christopher I Wright · Director
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
Craig C. Hopkinson · EVP R&D, Chief Medical Officer
Samuel Joseph Parisi · VP, Finance (Interim PAO)
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
Craig C. Hopkinson · EVP R, D, Chief Medical Office
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Craig C. Hopkinson · EVP R, D, Chief Medical Office
David Joseph Gaffin · EVP, CLO, Alkermes, Inc.
Samuel Joseph Parisi · VP, Finance (Interim PAO)
Christian Todd Nichols · SVP and Chief Commercial Officer
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Shane Cooke · Director
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Christian Todd Nichols · SVP and Chief Commercial Officer
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Christian Todd Nichols · SVP and Chief Commercial Officer
Samuel Joseph Parisi · VP, Finance (Interim PAO)
Cato T Laurencin · Director
Cato T Laurencin · Director
Cato T Laurencin · Director
Christian Todd Nichols · SVP and Chief Commercial Officer
Nancy Wysenski · Director
Christian Todd Nichols · SVP and Chief Commercial Officer
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Richard F Pops · Dir, CEO, Alkermes plc
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Shane Cooke · Director
Shane Cooke · Director
Blair Curtis Jackson · EVP and COO
Shane Cooke · Director
Shane Cooke · Director
Shane Cooke · Director
Craig C. Hopkinson · EVP R, D, Chief Medical Office
Craig C. Hopkinson · EVP R, D, Chief Medical Office
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.